Search Results

You are looking at 1 - 10 of 207 items :

  • "FDG-PET-CT" x
Clear All

J Pediatr Endocr Met 2012;25(3-4):233–237 © 2012 by Walter de Gruyter • Berlin • Boston. DOI 10.1515/jpem-2012-0029 *Corresponding author: Jigang Yang, Nuclear Medicine Department of Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, 100050 Beijing, China E-mail: Received February 4, 2012; accepted February 20, 2012; previously published online March 15, 2012 Brown adipose tissue: distribution and infl uencing factors on FDG PET/CT scan Ruirui Hao 1 , Leilei Yuan 2 , Nan Zhang 2

the FDG PET/CT scans most accurately and reproducibly for microbiology sample recovery and eradication of the suspicious focus. Computer-assisted navigation has become a useful tool in a broad variety of surgical applications. From our current experiences with these navigation systems, we hypothesized that the data sets of FDG PET/CT scans can be accurately used with navigation systems to access a potential septic bone focus. Materials and methods Artificial bone model The model used for this study consisted of an artificial femur bone (Sawbones, Malmö, Sweden). The

References 1. Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endocrinol Meta 2012; 26: 83-96. 2. Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab 2012; 97: 3866-75. 3. Treglia G, Muoio B, Giovanella L, Salvatori M. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol 2012; 270: 1783-7. 4. Cistaro A, Quartuccio N, Mojtahedi A, Fania P, Filosso PL

]fluorodeoxyglucose positron emission tomography. J Clin Oncol, 2006, 24, 5366–5372 [18] Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L et al. [18F]FDGPET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging, 2007, 34, 1915–1924 [19] Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67

nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2012; 39: 27-38. 21. Lee P, Bazan JG, Lavori PW, Weerasuriya DK, Quon A, Le QT, et al. Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non–small-cell lung cancer. Clin Lung Cancer 2012; 13: 52-8. 22. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010; 136: 883-9. 23. Giorgetti A, Sorace O, Pisani P, Salvadori PA, Mariani G

Cancer 2009; 45: 228-47. 6. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: 122S-50S. 7. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354: 496-507. 8. Evangelista L, Panunzio A, Polverosi R, Ferretti A, Chondrogiannis S, Pomerri F, et al. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging. Biomed Pharmacother 2012; 66: 448-53. 9. Qu X, Huang X, Yan W, Wu L, Dai K. A meta

R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 186-96. 19. Ravizzini G, Meirelles GS, Horwitz SM, Grewal RK. F-18 FDG uptake in subcutaneous panniculitis-like T-cell lymphoma. Clin Nucl Med 2008; 33: 903-5. 20. Kong EJ, Cho IH, Chun KA, Bae YK, Chol JH, Hyun MS. F-18 FDG PET/CT findings of subcutaneous panniculitis-like T-cell lymphoma: a case report. Nucl Med Mol Imaging 2009; 43: 240-4. 21. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, et al. Staging accuracy in mycosis fungoides and sezary syndrome

been claimed in previous studies that extranodal lymphomas should be regarded as separate nosological entities. 6 Computed tomography (CT) is the most frequently used imaging modality in the management of patients with PEL. CT, 18-fluorodeoxyglucose positron emission tomography (FDG-PET) and FDG-PET/CT are used to stage PEL. FDG-PET is a superior imaging technique which proved its utility especially in oncologic field. It is able to show functional alterations that precede the anatomical changes. Integration of CT to FDG-PET combines anatomical detail with

18 F-FDG PET/CT a promising modality for imaging the differential nociceptive activity in the spinal cord of LBP patients. 2 Materials and methods 2.1 Patients Approval for this study was obtained from our institutional review board, and data was collected in compliance with The Health Insurance Portability and Accountability Act (HIPAA). A retrospective review of 3500 PET/CT scans of patients with non-CNS cancers was performed between January 1,2006 and April 1, 2007 at Stanford University Medical Center. Among the exclusion criteria were significant motion

, Baum RP, Kirsch C. FDG PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin 2009; 48: 59-69. 5. Vansteenkiste J, Fisher BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-40. 6. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264: 559-66. 7. Goodgame B